<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432260</url>
  </required_header>
  <id_info>
    <org_study_id>C928-010</org_study_id>
    <nct_id>NCT03432260</nct_id>
  </id_info>
  <brief_title>A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis</brief_title>
  <acronym>AH</acronym>
  <official_title>An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CTI Clinical Trial &amp; Consulting Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Durect</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research trial testing DUR-928 (an experimental medication). The purpose of this
      trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of DUR 928
      in patients with moderate and severe alcoholic hepatitis (AH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of unexpected serious adverse reaction</measure>
    <time_frame>Screening to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total exposure (area under the curve)</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at maximum plasma concentration (Tmax)</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life</measure>
    <time_frame>Day 1 to Day 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Aspartate Aminotransferase (AST)</measure>
    <time_frame>Screening to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alanine Aminotransferase (ALT)</measure>
    <time_frame>Screening to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bilirubin</measure>
    <time_frame>Screening to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Model for End Stage Liver Disease (MELD) Score</measure>
    <time_frame>Screening to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lille Model for Alcoholic Hepatitis Score</measure>
    <time_frame>Screening to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high-sensitivity C-Reactive Protein (CRP)</measure>
    <time_frame>Screening to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Interleukin-18 (IL-18)</measure>
    <time_frame>Screening to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tumor Necrosis Factor (TNF) alpha</measure>
    <time_frame>Screening to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cytokeratin-18 (CK-18) M65</measure>
    <time_frame>Screening to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cytokeratin-18 (CK-18) M30</measure>
    <time_frame>Screening to Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>DUR-928</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation including 3 doses: 30mg, 90 mg and 150 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DUR-928</intervention_name>
    <description>Dose escalation including 3 doses: 30mg, 90 mg and 150 mg</description>
    <arm_group_label>DUR-928</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to provide written informed consent (either from patient or patient's legally
             acceptable representative)

          2. Male or female patients 21 years of age or older with BMI ≥ 20 to ≤ 40 kg/m2

          3. Patients with alcoholic hepatitis defined as:

               1. History of heavy alcohol abuse: &gt; 40 g/day in females or &gt; 60 g/day in males for
                  a minimum period of 6 months, AND

               2. Consumed alcohol within 12 weeks of entry into the study, AND

               3. Serum bilirubin &gt; 3 mg/dL AND AST &gt; ALT, but less than 300 U/L AND

               4. MELD score between 11-30, inclusive

          4. No evidence of active infection as determined by the investigator.

          5. Women of child-bearing potential must utilize appropriate birth control throughout the
             study duration.

          6. Male patients must agree to use a medically acceptable method of contraception/birth
             control throughout the study duration

        Exclusion Criteria:

          1. Other or concomitant cause(s) of liver disease as a result of:

               1. Autoimmune liver disease

               2. Wilson disease

               3. Vascular liver disease

               4. Drug induced liver disease

          2. Co-infection with human immunodeficiency virus (HIV) or Hepatitis B

          3. Any active malignancies other than curatively treated skin cancer (basal cell or
             squamous cell carcinomas)

          4. If female, known pregnancy, or has a positive serum pregnancy test, or
             lactating/breastfeeding

          5. Serum creatinine &gt; 2.5 mg/dL

          6. Patients who have had organ transplantation (such as liver, kidney, lung, heart, bone
             marrow, or stem cell etc.), other than cornea transplant

          7. Stage 3 or greater encephalopathy by West Haven criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Gordon, MD</last_name>
    <role>Study Director</role>
    <affiliation>CTI Clinical Trial &amp; Consulting Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah Scott, MS</last_name>
    <phone>408-777-1417</phone>
    <phone_ext>7471</phone_ext>
    <email>deborah.scott@durect.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christina Blevins, BS</last_name>
    <phone>408-777-1417</phone>
    <phone_ext>4973</phone_ext>
    <email>christina.blevins@durect.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DURECT Study Site 0001</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site 0003</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site 0004</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site 0002</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>DURECT Study Site 0005</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcoholic Hepatitis</keyword>
  <keyword>acute alcoholic liver disease</keyword>
  <keyword>progressive inflammatory liver injury</keyword>
  <keyword>IV infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

